PGC1α-mediated mitofusin-2 deficiency in female rats and humans with pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 8, 2013, Pages 865-878

  Ryan, John J ^a   Marsboom, Glenn ^a,b   Fang, Yong Hu ^a   Toth, Peter T ^a   Morrow, Erik ^a   Luo, Nancy ^a   Piao, Lin ^a   Hong, Zhigang ^a   Ericson, Kyle ^a   Zhang, Hannah J ^a   Han, Mei ^a   Haney, Chad R ^a   Chen, Chin Tu ^a   Sharp, Willard W ^a   Archer, Stephen L ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Female sex; Hypoxia inducible factor 1 ; Mitochondrial fission; Optic atrophy 1; Peroxisome proliferator activated receptor gamma coactivator 1

Indexed keywords

MITOFUSIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SEMAXANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG VASCULAR RESISTANCE; MITOFUSIN 2 DEFICIENCY; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EXERCISE TOLERANCE; FEMALE; GTP PHOSPHOHYDROLASES; HEAT-SHOCK PROTEINS; HUMANS; HYPERTENSION, PULMONARY; LUNG; MEMBRANE PROTEINS; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL PROTEINS; MYOCYTES, SMOOTH MUSCLE; OPTIC ATROPHY, AUTOSOMAL DOMINANT; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS;

EID: 84876848950     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201209-1687OC     Document Type: Article

References (55)

1. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010;137:376-387.
2. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-84.
3. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, et al . Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737-744. (Pubitemid 30659603)
4. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-1678. (Pubitemid 34298611)
5. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045-2066.
6. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-1087.
7. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thebaud B, Husain AN, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010;121:2661- 2671.
8. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113: 2630-2641. (Pubitemid 43948012)
9. Marsboom G, Toth PT, Ryan JJ, Hong Z, Wu X, Fang YH, Thenappan T, Piao L, Zhang HJ, Pogoriler J, et al. Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res 2012;110:1484-1497.
10. Wolin MS. Novel role for the regulation of mitochondrial fission by hypoxia inducible factor-1alpha in the control of smooth muscle remodeling and progression of pulmonary hypertension. Circ Res 2012;110:1395-1397.
11. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins MFN1 and MFN2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003; 160:189-200. (Pubitemid 36254953)
12. Neuspiel M, Zunino R, Gangaraju S, Rippstein P, McBride H. Activated mitofusin 2 signals mitochondrial fusion, interferes with bax activation, and reduces susceptibility to radical induced depolarization. J Biol Chem 2005;280:25060-25070. (Pubitemid 40934597)
13. Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. Opa1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci USA 2004;101:15927-15932. (Pubitemid 39507904)
14. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, Li P, Qiu X, Wen S, Xiao RP, et al. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 2004;6:872-883. (Pubitemid 39207252)
15. Koves TR, Li P, An J, Akimoto T, Slentz D, Ilkayeva O, Dohm GL, Yan Z, Newgard CB, Muoio DM. Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 2005;280:33588- 33598.
16. Soriano FX, Liesa M, Bach D, Chan DC, Palacin M, Zorzano A. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. Diabetes 2006;55: 1783-1791. (Pubitemid 44324133)
17. Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, Dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, et al. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy due to pulmonary arterial hypertension. Circ Heart Fail 2013;6:136-144.
18. Vescovo G, Ravara B, Gobbo V, Angelini A, Dalla Libera L. Skeletal muscle fibres synthesis in heart failure: role of PGC-1alpha, calcineurin and GH. Int J Cardiol 2005;104:298-306. (Pubitemid 41375590)
19. Mata M, Sarrion I, Milian L, Juan G, Ramon M, Naufal D, Gil J, Ridocci F, Fabregat-Andres O, Cortijo J. PGC-1alpha induction in pulmonary arterial hypertension. Oxid Med Cell Longev 2012;236572.
20. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121:2747- 2754.
21. Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, Thenappan T, Bache-Wiig P, Piao L, Paul J, et al . Lung (1)(8)ffluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185:670-679.
22. Choi SY, Huang P, Jenkins GM, Chan DC, Schiller J, Frohman MA. A common lipid links MFN-mediated mitochondrial fusion and snareregulated exocytosis. Nat Cell Biol 2006;8:1255-1262. (Pubitemid 44660590)
23. Rehman J, Zhang HJ, Toth PT, Zhang Y, Marsboom G, Hong Z, Salgia R, Husain AN, Wietholt C, Archer SL. Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. FASEB J 2012; 26:2175-2186.
24. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 2010;88:47-60.
25. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2010;299:L401-L412.
26. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-769. (Pubitemid 38338929)
27. Levett DZ, Radford EJ, Menassa DA, Graber EF, Morash AJ, Hoppeler H, Clarke K, Martin DS, Ferguson-Smith AC, Montgomery HE, et al. Acclimatization of skeletal muscle mitochondria to highaltitude hypoxia during an ascent of everest. FASEB J 2012;26:1431- 1441.
28. 2-sensitive potassium channel kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003;107:2037-2044.
29. 2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008;294:H570-H578.
30. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1998;114:225S-230S. (Pubitemid 28435972)
31. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc 2006;3:680-686. (Pubitemid 44788224)
32. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486-1495.
33. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:S13-S24.
34. Nasim MT, Ogo T, Chowdhury HM, Zhao L, Chen CN, Rhodes C, Trembath RC. BMPR-II deficiency elicits pro-proliferative and antiapoptotic responses through the activation of TGFbeta-TAK1-MAPK pathways in PAH. Hum Mol Genet 2012;21:2548-2558.
35. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104:1342-1347. (Pubitemid 46184006)
36. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-1491. (Pubitemid 40814657)
37. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 2002;121:97S-98S. (Pubitemid 34248379)
38. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821. (Pubitemid 41434408)
39. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008;33:278- 291.
40. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, et al. Role for MIR-204 in human pulmonary arterial hypertension. J Exp Med 2011;208:535- 548.
41. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, Cottrill KA, Shaik RS, Waxman AB, Zhang YY, et al. Microrna-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012;125:1520-1532.
42. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007;104:11418-11423. (Pubitemid 47175155)
43. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001;195:367-374.
44. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie- Tooth neuropathy type 2A. Nat Genet 2004;36:449-451. (Pubitemid 38620027)
45. Liesa M, Borda-d'Agua B, Medina-Gomez G, Lelliott CJ, Paz JC, Rojo M, Palacin M, Vidal-Puig A, Zorzano A. Mitochondrial fusion is increased by the nuclear coactivator PGC-1beta. PLoS ONE 2008;3: e3613.
46. Cartoni R, Leger B, Hock MB, Praz M, Crettenand A, Pich S, Ziltener JL, Luthi F, Deriaz O, Zorzano A, et al.Mitofusins 1/2 and ERRalpha expression are increased in human skeletal muscle after physical exercise. J Physiol 2005;567:349-358. (Pubitemid 41167327)
47. Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, Podvinec M, Oakeley EJ, Kralli A. The estrogen-related receptor alpha (ERRalpha) functions in ppargamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci USA 2004;101:6472- 6477.
48. Liu D, Zhang Z, Gladwell W, Teng CT. Estrogen stimulates estrogenrelated receptor alpha gene expression through conserved hormone response elements. Endocrinology 2003;144:4894-4904. (Pubitemid 37378404)
49. Mori T, Sawada M, Kuroboshi H, Tatsumi H, Katsuyama M, Iwasaku K, Kitawaki J. Estrogen-related receptor alpha expression and function are associated with vascular endothelial growth factor in human cervical cancer. Int J Gynecol Cancer 2011;21:609-615.
50. Guo X, Chen KH, Guo Y, Liao H, Tang J, Xiao RP. Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ Res 2007;101:1113-1122. (Pubitemid 350146437)
51. Zhang D, Ma C, Li S, Ran Y, Chen J, Lu P, Shi S, Zhu D. Effect of mitofusin 2 on smooth muscle cells proliferation in hypoxic pulmonary hypertension. Microvasc Res 2012;84:286-296.
52. Wan-Xin T, Tian-Lei C, Ben W, Wei-Hua W, Ping F. Effect of mitofusin 2 overexpression on the proliferation and apoptosis of high-glucoseinduced rat glomerular mesangial cells. J Nephrol 2012;25:1023-1030.
53. McMurtry MS, Moudgil R, Hashimoto K, Bonnet S, Michelakis ED, Archer SL. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;292:L872-L878. (Pubitemid 46608233)
54. Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, Palacin M, Zorzano A. The Charcot-Marie-Tooth type 2A gene product, MFN2, up-regulates fuel oxidation through expression of oxphos system. Hum Mol Genet 2005;14:1405-1415. (Pubitemid 40823451)
55. Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath JR, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem 2003;278:17190-17197. (Pubitemid 36799599)